邢丹,
臧砚超,
张宏伟,
彭晨
唐山市第二医院 ICU，唐山 河北 063000

详细信息 作者简介: 邢 丹（1986-），女，主治医师。E-mail：532049969@qq.com




中图分类号: R619


摘要:目的探讨血必净联合甲强龙对脂肪栓塞综合征患者的治疗作用。方法选取2015年7月至2020年7月唐山市第二医院收治的脂肪栓塞综合征患者共40例，根据治疗方式不同，分为甲强龙治疗组（A组）及血必净联合甲强龙治疗组（B组）。其中A组19例，B组21例。A组患者应用甲强龙0.1 g每日1次静脉滴注及对症支持治疗；B组患者应用甲强龙 0.1 g每日1次静脉滴注，同时联合血必净50 mL每日2次静脉滴注及对症支持治疗；两组均连用5 d。比较两组患者治疗前后血氧饱和度、动脉血氧分压、血红蛋白、血小板及心率等结果的差异。结果A组患者血氧饱和度、动脉血氧分压、血红蛋白、血小板及心率治疗前分别（81.89±2.00）%，（59.00±3.35）mmHg，（85.58±2.80）g/L，（68.21±2.64）×10⁹/L，（136.32±4.89）次/min；治疗后分别为（91.89±1.49）%，（80.95±3.98）mmHg，（108.00±2.91）g/L，（94.05±2.90）×10⁹/L，（96.89±3.59）次/min。B组患者血氧饱和度、动脉血氧分压、血红蛋白、血小板及心率治疗前分别为（81.90±2.05）%，（59.05±3.46）mmHg，（85.05±3.12）g/L，（67.90±2.62）×10⁹/L，（135.76±5.32）次/min；治疗后分别为（98.43±1.33）%，（99.05±1.99）mmHg，（126.48±2.28）g/L，（113.43±1.94）×10⁹/L，（72.43±3.89）次/min。两组患者治疗后各项指标均较治疗前好转，差异有统计学意义（P＜0.05），且B组治疗后各项指标较A组治疗后好转更加显著，差异有统计学意义（P＜0.05）。结论血必净在脂肪栓塞的治疗中可与甲强龙起协同治疗作用，有利于患者的治疗及改善预后。
关键词: 血必净注射液/
甲强龙/
脂肪栓塞


Abstract:ObjectiveTo investigate the therapeutic effect of Xuebijing combined with methylprednisolone on patients with fat embolism syndrome.MethodsA total of 40 patients with fat embolism syndrome admitted to our department from July 2015 to July 2020 were selected and divided into group A and group B according to different treatment methods. There were 19 cases in group A and 21 cases in group B. Patients in group A were given methylprednisolone 0.1 g intravenous infusion and symptomatic supportive treatment, while patients in group B were given methylprednisolone 0.1 g intravenous infusion combined with Xuebijing 50 mL intravenous infusion 2 times/day and symptomatic supportive treatment. The differences of blood oxygen saturation, arterial partial pressure of oxygen, hemoglobin, platelet and heart rate before and after treatment were compared between the two groups.ResultsThe blood oxygen saturation, arterial partial pressure of oxygen, hemoglobin, platelet and heart rate of group A before treatment were (81.89±2.00)%, (59.00±3.35) mmHg, (85.58±2.80) g/L, (68.21±2.64)×10⁹/L, (136.32±4.89) times/min, respectively. After treatment, those indicators were (91.89±1.49)%, (80.95±3.98) mmHg, (108.00±2.91) g/L, (94.05±2.90)×10⁹/L, (96.89±3.59) times/min, respectively. Before treatment, the blood oxygen saturation, arterial partial pressure of oxygen, hemoglobin, platelet and heart rate of group B were (81.90±2.05)%, (59.05±3.46) mmHg, (85.05±3.12) g/L, (67.90±2.62) ×10⁹/L, (135.76±5.32) times/min, respectively. After treatment, those indicators were (98.43±1.33)%, (99.05±1.99) mmHg, (126.48±2.28) g/L, (113.43±1.94) ×10⁹/L, (72.43±3.89) times/min, respectively. After treatment, the indicators of the two groups were improved compared with those before treatment, and the differences were statistically significant (P＜0.05); the indicators of group B were improved more significantly than those of group A after treatment, and the differences were statistically significant (P＜0.05).ConclusionXuebijing and methylprednisolone can play a synergistic role in the treatment of fat embolism, which is beneficial to the treatment of patients and improve the prognosis.
Keywords:Xuebijing injection/
methylprednisolone/
fat embolism syndrome

PDF全文下载地址:

https://journal.dmu.edu.cn/data/article/export-pdf?id=63bcf851fa89b26d52c94a30